Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Gjelsvik YM, Myklebust TÅ, Fosså SD, Haug ES, Kvåle R, Ursin G, Johannesen TB(2025) A nationwide, longitudinal collection of patient-reported outcomes from prostate cancer patients and controls Qual Life Res(in press) DOI 10.1007/s11136-025-04017-7, PubMed 40603678
Fleur du Pré M, Kleppa L, Dewan AE, Meling MT, Høydahl LS, Besser HA, Khosla C, Sollid LM(2025) Peyer's patch B cells sample transglutaminase-gluten complexes and drive celiac disease autoimmunity Gastroenterology(in press) DOI 10.1053/j.gastro.2025.06.021, PubMed 40602545
Lindemann K, Berton D, Sehouli J, Christensen RD, Altintas S, Knudsen AØ, Heudel PE, Ataseven B, Vergote I, Lindahl G, Lebreton C, Schochter F, Auranen A, Follana P, Madsen K, Selle F, Petersson KS, Joly F, Braicu EI, Mirza MR(2025) NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer Gynecol Oncol, 199, 79-87(in press) DOI 10.1016/j.ygyno.2025.06.008, PubMed 40592025